NCT05268198 is a EARLY_PHASE1 clinical trial of APR002 in COVID-19, sponsored by Global Health Drug Discovery Institute.

Who is sponsoring NCT05268198?

NCT05268198 is sponsored by Global Health Drug Discovery Institute.

What drugs are being tested in NCT05268198?

Interventions in NCT05268198: APR002, Placebo.

Is NCT05268198 still recruiting?

NCT05268198 is currently completed. Last updated 2 August 2023.

Last reviewed 2023-08-02 · How we verify

NCT05268198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects

Completed EARLY_PHASE1 Last updated 2 August 2023

What this trial tests

EARLY_PHASE1 trial testing APR002 in COVID-19 in 42 participants. Completed in 27 July 2023.

Timeline

20 March 2023

Primary endpoint
29 June 2023

27 July 2023

Quick facts

Lead sponsor	Global Health Drug Discovery Institute
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	42
Start date	20 March 2023
Primary completion	29 June 2023
Estimated completion	27 July 2023
Sites	1 location across Australia

Drugs / interventions tested

APR002 — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Global Health Drug Discovery Institute

Who can join

Adults 18 to 55, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APR002 in healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The progress of molecules and strategies for the treatment of HBV infection.
Pan Y, Xia H, He Y, Zeng S, et al · · 2023 · cited 33× · PMID 37009498 · DOI 10.3389/fcimb.2023.1128807

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05268198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Global Health Drug Discovery Institute
Last refreshed: 2 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing